Riester Z, Hüser L, Sun Q, Nagibin V, Kirschning C, Bronte V, Utikal J, Altevogt P, Umansky V. Melanoma extracellular vesicles induce immunosuppressive myeloid cells by PD-L1 upregulation via TLR4 signaling Utikal, Viktor Umansky. Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression. Br J Cancer (accepted) Huber V, Vallacchi V, Fleming V, Hu X, Cova A, Dugo M, Shahaj M, Sulsenti R, Vergani E et al. miRNAs delivered by tumor extracellular vesicles

more »

... e myeloid suppressor cells in melanoma patients and predict resistance to immunotherapy J of Clin Invest 2018 Sep Weber R, Fleming V, Hu X, Nagibin V, Groth C, Altevogt P, Utikal J, Umansky V. Myeloidderived suppressor cells hinder the anti-cancer activity of immune checkpoint inhibitors. Front. Immunol. 2018 June Fleming V, Hu X, Weber R, Nagibin V, Groth C, Altevogt P, Utikal J, Umansky V. Review: Targeting myeloid-derived suppressor cells to bypass tumor-induced immunosuppression. Front. Immunol. Razon et al. CCR5+ myeloid-derived suppressor cells are enriched and activated in melanoma lesions. Cancer Res. 2018 Jan (*equally contributed) Fleming V & Umansky V. Editorial: Two MDSC faces in obesity: correcting metabolic dysfunctions but promoting tumor development. J of Leukocyte Biology. 2017 Dec Sammar M, Siwetz M, Meiri H, Fleming V, Altevogt P, Huppertz B. Expression of CD24 and Siglec-10 in first trimester placenta: implications for immune tolerance at the fetal-maternal interface. Histochem Cell Biol. 2017 May Umansky V, Blattner C, Fleming V, Hu X, Gebhardt C, Altevogt P, Utikal J. Myeloid-derived suppressor cells and tumor escape from immune surveillance. Semin Immunopathol. 2017 Apr Mairhofer DG, Ortner D, Tripp CH, Schaffenrath S, Fleming V, Heger L, Komenda K, Reider D, et al. Impaired gp100-specific CD8(+) T-Cell responses in the presence of myeloidderived suppressor cells in a spontaneous mouse melanoma model. J Invest Dermatol. CIMT -The association for cancer immunotherapy in Mainz, Germany verlangsamtes Wachstum in vivo von HSP86 defizienten Tumoren, welche mit einer Reduktion von PD-L1 auf MDSC im Tumormikromillieu einherging. Zusammengefasst demonstrieren wir in dieser Arbeit eine kritische Rolle von HSP86 auf Tumor Vesikeln in der Konvertierung von IMC zu MDSC. Somit ist HSP86 ein vielversprechender Angriffspunkt für die Immuntherapie. immunosurveillance concept. However, the lack of experimental designs and technologies made it impossible to prove the concept. In 1990, new mouse models, genetic engineering and monoclonal antibodies provided the opportunity to prove the immunosurveillance hypothesis [29] . Robert Schreiber and colleagues proposed a revised version of the immunosurveillance concept, which was termed immunoediting and comprises of three different phases: elimination, equilibrium and escape [29]